Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia | Zendy

Angela Vincent | Zendy; Philippa Pettingill | Zendy; R Pettingill | Zendy; Bethan Lang | Zendy; Ron Birch | Zendy; Patrick Waters | Zendy; Sarosh R. Irani | Zendy; Camilla Buckley | Zendy; Osamu Watanabe | Zendy; Kimiyoshi Arimura | Zendy; Matthew C. Kiernan | Zendy

Open Access

Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia

Author(s) -

Angela Vincent,

Philippa Pettingill,

R Pettingill,

Bethan Lang,

Ron Birch,

Patrick Waters,

Sarosh R. Irani,

Camilla Buckley,

Osamu Watanabe,

Kimiyoshi Arimura,

Matthew C. Kiernan

Publication year - 2018

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2018.2681

Subject(s) - medicine , neuromyotonia , cohort , autoantibody , modified rankin scale , serology , antibody , gastroenterology , immunology , ischemic stroke , ischemia

Although acquired autoimmune neuromyotonia (NMT) is associated with voltage-gated potassium channel (VGKC)-complex antibodies, to date there has been no systematic study of autoantibodies to the specific antigens leucine-rich glioma inactivated protein 1 (LGI1), contactin-associated protein 2 (CASPR2), and contactin 2 together with the full clinical syndrome, particularly pain and autonomic and central nervous system involvement.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research